Candriam S.C.A. Akebia Therapeutics, Inc. Transaction History

Candriam S.C.A.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Jan 22, 2021	SELL	$2.22 - $3.78 $155,400 - $264,600	-70,000 Closed	0 $0
Q3 2020 Oct 19, 2020	SELL	$2.39 - $13.08 $2.77 Million - $15.2 Million	-1,159,346 Reduced 94.31%	70,000 $176,000
Q2 2020 Jul 23, 2020	BUY	$6.67 - $13.58 $8.2 Million - $16.7 Million	1,229,346 New	1,229,346 $16.7 Million
Q4 2019 Jan 21, 2020	SELL	$3.16 - $6.73 $948,000 - $2.02 Million	-300,000 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$5.39 - $9.15 $1.24 Million - $2.1 Million	230,000 Added 328.57%	300,000 $1.66 Million
Q3 2018 Nov 07, 2018	BUY	$7.44 - $10.65 $520,800 - $745,500	70,000 New	70,000 $618,000

121

54.6M

291K

179K

Ticker AKBA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 183,848,992
Market Cap $349M
Description
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...

Get notified when there are updates to the investment portfolio of Candriam S.C.A., based on Form 13F filings with the SEC.

Stay updated on Candriam S.C.A. with notifications on news.